|
Characteristic
|
Entire cohort (n = 132)
|
CC-CCD, mg/m2
|
P valuea
|
|---|
|
< 160 (n = 52, %)
|
≥ 160 (n = 80, %)
|
|---|
|
Sex
|
0.354
|
|
Male
|
92 (69.7)
|
39 (75.0)
|
53 (66.2)
| |
|
Female
|
40 (30.3)
|
13 (25.0)
|
27 (33.8)
| |
|
Age, years
|
0.494
|
|
≤ 15
|
69 (52.3)
|
25 (48.1)
|
44 (55.0)
| |
|
< 15
|
63 (47.7)
|
27 (51.9)
|
36 (45.0)
| |
|
Smoking history
|
0.170
|
|
No
|
123 (93.2)
|
46 (88.5)
|
77 (96.2)
| |
|
Yes
|
9 (6.8)
|
6 (11.5)
|
3 (3.8)
| |
|
BMI, m2
|
0.310
|
|
≤ 1.45
|
64 (48.5)
|
22 (42.3)
|
42 (52.5)
| |
|
> 1.45
|
68 (51.5)
|
30 (57.7)
|
38 (47.5)
| |
|
EBV DNA, copy/mL
|
0.293
|
|
< 4000
|
52 (39.4)
|
17 (32.7)
|
35 (43.7)
| |
|
≥ 4000
|
80 (60.6)
|
35 (67.3)
|
45 (56.3)
| |
|
T stageb
|
0.281
|
|
T1
|
1 (0.8)
|
1 (1.9)
|
0 (0)
| |
|
T2
|
4 (3.0)
|
1 (1.9)
|
3 (3.8)
| |
|
T3
|
59 (44.7)
|
27 (51.9)
|
32 (40.0)
| |
|
T4
|
68 (51.5)
|
23 (44.2)
|
45 (56.3)
| |
|
N stageb
|
0.165
|
|
N0
|
1 (0.8)
|
1 (1.9)
|
0 (0)
| |
|
N1
|
18 (13.6)
|
8 (15.4)
|
10 (12.5)
| |
|
N2
|
65 (49.2)
|
29 (55.8)
|
36 (45.0)
| |
|
N3
|
48 (36.4)
|
14 (26.9)
|
34 (42.5)
| |
|
Overall stageb
|
0.114
|
|
III
|
36 (27.3)
|
19 (36.5)
|
17 (21.3)
| |
|
IVA
|
48 (36.4)
|
19 (36.5)
|
29 (36.2)
| |
|
IVB
|
48 (36.4)
|
14 (26.9)
|
34 (42.5)
| |
|
NAC cycles
|
0.062
|
|
2
|
60 (45.5)
|
30 (57.7)
|
30 (37.5)
| |
|
3
|
66 (50.0)
|
21 (40.4)
|
45 (56.3)
| |
|
4
|
6 (4.5)
|
1 (1.9)
|
5 (6.2)
| |
|
NAC regimens
|
< 0.001
|
|
TPF
|
73 (55.3)
|
18 (34.6)
|
55 (68.8)
| |
|
TP
|
20 (15.2)
|
13 (25.0)
|
7 (8.8)
| |
|
PF
|
35 (26.5)
|
21 (40.4)
|
14 (17.5)
| |
|
GP
|
4 (3.0)
|
0 (0.00)
|
4 (5.0)
| |
|
Adjuvant chemotherapy
|
0.575
|
|
No
|
129 (97.7)
|
50 (96.1)
|
79 (98.7)
| |
|
Yes
|
3 (2.3)
|
2 (3.9)
|
1 (1.3)
| |
|
NAC-CCD, mg/m2
|
0.112
|
|
< 180
|
62 (47.0)
|
29 (55.8)
|
33 (41.3)
| |
|
≥ 180
|
70 (53.0)
|
23 (44.2)
|
47 (58.7)
| |
|
Radiation dose, cGy
|
0.386
|
|
< 6800
|
64 (49.6)
|
22 (44.0)
|
42 (53.2)
| |
|
≥ 6800
|
65 (50.4)
|
28 (56.0)
|
37 (46.8)
| |
- CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, BMI body mass index, EBV Epstein–Barr virus, NAC neoadjuvant chemotherapy, TPF cisplatin with 5-fluorouracil and toxoids, TP cisplatin with toxoids, PF cisplatin with 5-fluorouracil, GP cisplatin with gemcitabine, NAC-CCD cumulative cisplatin dose during neoadjuvant chemotherapy
-
aP values were calculated using the chi-square test or Fisher exact test if indicated
-
bAccording to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system
